Excess iron undermined bone load-bearing capacity through tumor necrosis factor-α-dependent osteoclastic activation in mice

Introduction

Bone mass is maintained by the balance of bone formation and resorption, involving a number of regulatory pathways. Bone formation is performed by osteoblasts, while bone resorption is carried out by osteoclasts. Disruptions of these processes are likely to induce hyperosteogeny or osteopenia (1,2). Numerous clinical studies reported that patients with osteoporosis showed iron accumulation in the bone, potentially leading to pathological damages, such as occurred femoral neck fractures in patients of African descent (3–5).

Ovariectomized rats with an increased iron level showed a higher tendency to have osteoporosis (6). Tsay et al(7) reported that the iron overload (IO)-induced bone loss in mice was correlated with the inflammatory bone resorption and oxidative stress. Using in vitro cell assays, iron treatment was demonstrated to inhibit osteoblast formation, proliferation and mineralization (8–10), while promoting osteoclast differentiation and increased osteoclastic function (11). Therefore, IO is believed to disrupt bone metabolism and induce bone loss.

Iron accumulation in tissue is likely to provoke the formation of reactive oxygen species (ROS) (12), while the iron excess is likely to induce an increased expression of tumor necrosis factor-α (TNF-α) (13). However, the contribution of oxidative stress to osteoporosis was also recognized (14,15). ROS induced increased TNF-α expression and activated several signaling systems involved in the osteoclastic differentiation, especially the nuclear factor-κB (NF-κB) pathway. TNF-α was found to synergize strongly with the receptor activator of NF-κB ligand in osteoclast formation and activation (16,17). Therefore, osteoclastic hyperresorption was highly involved in ROS- and TNF-α-induced bone loss. However, whether IO is linked to induced bone function impairment has yet to be investigated.

In this study, a mouse model with IO was developed and was used to determine whether the excess iron undermined bone strength and load-bearing capacity through TNF-α induction and osteoclastic function promotion.

Materials and methods

Animal experiments

Six-week-old female BALB/c mice were fed under sterile conditions and divided into two groups. The iron excess (i.e., IO), group was injected with iron-dextran (Sigma, St. Louis, MO, USA) at 250 mg/kg. The control mice were injected with equal amounts of phosphate-buffered saline (PBS) twice a week for four weeks. Subsequent to sacrificing the animals at 48 h after the final injection, blood and femur samples were collected for analysis.

Assessments of bone metabolic markers

Blood samples were collected from the heart and allowed to clot at room temperature. Serum samples were separated from the blood by centrifugation at 3,000 rpm for 10 min. Serum osteocalcin, C-telopeptide of type I collagen (CTX-1) and TNF-α were measured by ELISA (Rapidbio; RapidBio, West Hills, CA, USA; R&D Systems, Minneapolis, MN, USA), according to the manufacturer’s instructions.

Bone biomechanical analysis

Biomechanical properties of femurs were measured by the three-point bending test performed using a universal material test machine (AG-1S; Shimadzu Co., Kyoto, Japan) at room temperature, as described in previous studies (18–20). Briefly, the diaphysis was placed on two supports with a span of 10 mm, while the loading pin was centered above two supports at a displacement rate of 2 mm/min, until fracture occurred.

Statistical analysis

The two-tailed Student’s t-test was used to analyze experimental data. The data were presented as the means ± standard error (SE). P<0.05 was considered to indicate a statistically significant difference.

Results and Discussion

Mechanical loading sends signals which are essential for bone mass maintenance and strength depending on the stimulus (21). To determine whether IO undermines the bone strength and function, the biomechanical parameters of the bone were measured. Maximal bending stress is the maximum load per unit of bone area in the plastic deformation stage, while the modulus of bending elasticity involves the resistance to elastic deformation of the bone, reflecting the inner strength of the bone, without size effect. As shown in Fig. 1A, the maximal bending stress was reduced approximately by 20% (P=0.03) under IO conditions, while the modulus of bending elasticity was reduced by 30% (P=0.05, Fig. 1B). These findings suggested that IO led to a significant reduction of bone load-bearing capacity and thus increased the risk of fractures.

Figure 1. Excess iron impaired biomechanical properties of femurs from mice with IO are shown. (A) Maximal bending stress was measured by the three-point bending test for femurs from mice with IO treatment and control mice (n=8–9). (B) Modulus of bending elasticity using the three-point bending test for femurs upon IO condition (n=8–9) is shown.

Bone load-bearing capacity is dependent on bone formation, as well as bone resorption. To gain insight into the mechanism underlying the IO-mediated impairment to bone load-bearing capacity, the osteocalcin and CTX-1 were measured. Osteocalcin is secreted by osteoblasts in the maturation stage to sustain mineralization and may be used as a marker of bone formation in the evaluation of bone mass. The findings of this study showed no statistically significant difference in the osteocalcin content between the mice with IO and the control group (28.82 vs. 28.99, P=0.963, Fig. 2A). In contrast to these findings, in their study, Yamasaki et al(8) demonstrated that excess iron reduced the mineralization of rat calvarial osteoblast-like cells by showing a decreased number of mineralized nodules (9,10). This discrepancy may be due to the in vitro sensitivity of osteoblasts being higher compared to the in vivo, when directly exposed to iron. Thus, consistent with another in vivo study (7), our results demonstrated that IO had little effect on bone formation.

Figure 2. Excess iron provoked bone resorption. (A) Serum osteocalcin assayed by ELISA in the groups (n=9) is shown. (B) CTX-1 assessed by ELISA in the two groups (n=5–9) is shown.

CTX-1 is the degraded product of type I collagen with an enhanced osteoclastic activity, used to evaluate the bone resorptive process. In the present study, the CTX-1 content was observed to be notably increased (∼50%) in the IO group compared to the control group (P=0.008, Fig. 2B), suggesting an elevated bone resorption.

The increased bone resorption indicated that the osteoclastic activity was stimulated. Since IO was demonstrated to induce the TNF-α expression that further triggers osteoclastic function (13,22,23), the TNF-α level was measured. Consistent with a previous study (13), the TNF-α level in the IO mice was approximately 1.5-fold higher compared to the control group (Fig. 3), as shown. TNF-α was demonstrated to be involved in the enhancement of the development of osteopenia and osteoporosis (14,15). TNF-α promoted osteoclastogenesis through synergizing with a permissive level of the receptor activator of NF-κB ligand (RANKL), as well as through directly affecting osteoclasts (16,17). In the current study, a high serum TNF-α level was observed in mice with IO. The increased TNF-α is likely to promote the osteoclastic function and enhance inflammatory osteolysis, resulting in advanced bone resorption (24). Therefore, upon IO exposure, although increased TNF-α was not involved in mineralization inhibition, it accelerated bone loss and eventually reduced bone strength.

Figure 3. Excess iron increased serum TNF-α. Serum TNF-α measured by ELISA from mice with IO treatment and the control mice (n=8) is shown.

In conclusion, the findings of the present study have shown that IO undermined bone load-bearing capacity through the enhancement of TNF-α secretion, which facilitated osteoclastic differentiation and promoted the bone-resorbing activity (Fig. 4). Therefore, decreasing the iron burden is likely to be a promising approach for the treatment of bone metabolic diseases, such as osteopenia and osteoporosis.

Figure 4. A schematic delineation of the mechanism responsible for IO-triggered impairment to bone strength is shown. IO largely increased serum TNF-α content by stimulating inflammatory cells through ROS induction. Consequently, increased TNF-α promoted osteoclastogenesis, then activated osteoclastic function stimulated bone resorption. However, excess iron had little effect on bone formation. As a result, bone mass was reduced and bone load-bearing capacity was undermined.

Acknowledgements

This study was financed by grants from the Chinese Academy of Sciences (KZCX2-EW-404) and the National Natural Science Foundation of China (nos. 21077128, 20921063 and 21177151). The authors would like to thank the laboratory staff members for their assistance with the experiments and reagents.

References